Ivabradine — Membership Pricing

Other medications in Heart & Cardiovascular

• Ivabradine (CAD)
• Labetalol
• Lisinopril
• Losartan
• Lovastatin
• Macitentan
• Metolazone
• Metoprolol

What Ivabradine is approved for (FDA label)

Ivabradine tablets are a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) 1.1 Heart Failure in Adult Patients Ivabradine tablets are indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.

Source: Read the full FDA label on DailyMed. Label effective date: August 20, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ivabradine (FDA label)

Ivabradine tablets 5 mg: orange colored, capsule shaped, film-coated tablets, functionally scored with debossing "M" & "I" on one side and "2" on other side. The tablet is scored and can be divided into equal halves to provide a 2.5 mg dose. 7.5 mg: orange colored, round shaped, film-coated tablets debossed with “MI” on one side and “1” on the other side. Tablets: 5 mg, 7.5 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 676907d3-b374-4baa-8422-c04706409540. SPL document ID: c154911d-3174-409f-9619-3fe38dda4dbd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ivabradine (FDA label)

Clinically significant adverse reactions that appear in other sections of the labeling include: • Atrial Fibrillation [ see Warnings and Precautions (5.2) ] • Bradycardia and Conduction Disturbances [ see Warnings and Precautions (5.3) ] Most common adverse reactions occurring in ≥ 1% of patients are bradycardia, hypertension, atrial fibrillation and luminous phenomena (phosphenes). ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals, LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 676907d3-b374-4baa-8422-c04706409540. SPL document ID: c154911d-3174-409f-9619-3fe38dda4dbd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ivabradine (FDA label)

Ivabradine is contraindicated in patients with: • Acute decompensated heart failure • Clinically significant hypotension • Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present • Clinically significant bradycardia [ see Warnings and Precautions (5.3) ] • Severe hepatic impairment [ see Use in Specific Populations (8.6) ] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [ see Drug Interactions (7.3) ] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [ see Drug Interactions (7.1) ] • Acute decompensated heart failure ( 4 ) • Clinically significant hypotension ( 4 ) • Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present ( 4 ) • Clinically significant bradycardia ( 4 ) • Severe hepatic impairment ( 4 ) • Heart rate maintained exclusively by the pacemaker ( 4 ) • In combination with strong cytochrome CYP3A4 inhibitors ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 676907d3-b374-4baa-8422-c04706409540. SPL document ID: c154911d-3174-409f-9619-3fe38dda4dbd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ivabradine (FDA label)

• Fetal toxicity: Females should use effective contraception. ( 5.1 ) • Monitor patients for atrial fibrillation. ( 5.2 ) • Monitor heart rate decreases and bradycardia symptoms during treatment. ( 5.3 ) • Not recommended in patients with 2 nd degree AV block. ( 5.3 ) 5.1 Fetal Toxicity Ivabradine may cause fetal toxicity when administered to a pregnant woman based on findings in animal studies. Embryo-fetal toxicity and cardiac teratogenic effects were observed in fetuses of pregnant rats treated during organogenesis at exposures 1 to 3 times the human exposures (AUC 0-24hr ) at the maximum recommended human dose (MRHD) [ see Use in Specific Populations (8.1) ] . Advise females of reproductive potential to use effective contraception when taking ivabradine [ see Use in Specific Populations (8.3) ] . 5.2 Atrial Fibrillation Ivabradine increases the risk of atrial fibrillation.

Source: FDA prescribing information (DailyMed). Set ID: 676907d3-b374-4baa-8422-c04706409540. SPL document ID: c154911d-3174-409f-9619-3fe38dda4dbd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ivabradine (FDA label)

Avoid CYP3A4 inhibitors or inducers. ( 7.1 ) Negative chronotropes increase risk of bradycardia, monitor heart rate. ( 7.2 ) 7.1 Cytochrome P450-Based Interactions Ivabradine is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [ see Contraindications (4) and Clinical Pharmacology (12.3) ] . Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use of moderate CYP3A4 inhibitors when using ivabradine. Examples of moderate CYP3A4 inhibitors include diltiazem, verapamil, and grapefruit juice [ see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3) ] . Avoid concomitant use of CYP3A4 inducers when using ivabradine. Examples of CYP3A4 inducers include St.

Source: FDA prescribing information (DailyMed). Set ID: 676907d3-b374-4baa-8422-c04706409540. SPL document ID: c154911d-3174-409f-9619-3fe38dda4dbd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.